An Anti-CAPN5 Intracellular Antibody Acts As an Inhibitor of CAPN5-mediated Neuronal Degeneration
Overview
Authors
Affiliations
has been linked to autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV). Activation of CAPN5 may increase proteolysis and degradation of a wide range of substrates to induce degeneration in the retina and the nerve system. Thus, we developed an inhibitory intracellular single chain variable fragment (scFv) against CAPN5 as a potential way to rescue degeneration in ADNIV disease or in neuronal degeneration. We report that overexpression CAPN5 increases the levels of the auto-inflammatory factors toll like receptor 4 (TLR4), interleukin 1 alpha (IL1alpha), tumor necrosis factor alpha (TNFalpha) and activated caspase 3 in 661W photoreceptor-like cells and SHSY5Y neuronal-like cells. Both C4 and C8 scFvs specifically recognize human/mouse CAPN5 in 661W cells and SHSY5Y cells, moreover, both the C4 and C8 scFvs protected cells from CAPN5-induced apoptosis by reducing the levels of activated caspase 3 and caspase 9. The cellular expression C4 scFv reduced levels of the pro-inflammatory factor IL1-alpha activated caspase 3 in cells after CAPN5 overexpression. We suggest that CAPN5 expression has important functional consequences in auto-inflammatory processes, and apoptosis in photoreceptor like cells and neural-like cells. Importantly, the specific intracellular targeting of antibody fragments blocking activation of CAPN5 act as inhibitors of CAPN5 functions in neural like cells, thus, our data provides a novel potential tool for therapy in CAPN5-mediated ADNIV or neurodegenerative diseases.
Maccora I, Ebert J, Schulert G, Quinlan-Waters M, Duell A, Huggins J Ocul Immunol Inflamm. 2024; 32(10):2441-2448.
PMID: 39254738 PMC: 11598639. DOI: 10.1080/09273948.2024.2401146.
Calpains as mechanistic drivers and therapeutic targets for ocular disease.
Vu J, Wang E, Wu J, Sun Y, Velez G, Bassuk A Trends Mol Med. 2022; 28(8):644-661.
PMID: 35641420 PMC: 9345745. DOI: 10.1016/j.molmed.2022.05.007.
Boyce T, Whitmore S, Varzavand K, Russell S, Sohn E, Folk J Am J Ophthalmol. 2021; 233:144-152.
PMID: 34302771 PMC: 9177238. DOI: 10.1016/j.ajo.2021.07.015.
Karelia D, Kim S, Pandey M, Plano D, Amin S, Lu J Int J Mol Sci. 2021; 22(9).
PMID: 34067020 PMC: 8124556. DOI: 10.3390/ijms22094966.
CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials.
Wert K, Koch S, Velez G, Hsu C, Mahajan M, Bassuk A Hum Mutat. 2019; 40(12):2377-2392.
PMID: 31403230 PMC: 7493429. DOI: 10.1002/humu.23894.